A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma

This is a multicenter, single arm, open-label study. The purpose of the study is to evaluate safety of Prizloncabtagene Autoleucel (Prizlon-cel) and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of Prizlon-cel (Phase 2) in patients with relapsed or refractory large b-cell lymphoma (LBCL).

Trial Details

NCT ID
NCT05800977
Phase
PHASE1 / PHASE2
Sponsor
Shanghai AbelZeta Ltd.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Prizloncabtagene autoleucel
Locations (sample)
  • Beijing, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723
  • Chongqing, China|29.56026,106.55771
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • ≥ 18 years of age
  • Histologically confirmed CD19 or CD20 positive B-cell non-Hodgkin lymphoma, including the following neoplasms as defined by the 2016 WHO classifica…
  • Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)
  • Primary mediastinal large B-cell lymphoma (PMBCL)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →